Скачать или смотреть Abliva - Introducing Mitochondrial “Mito” Disease - World Mitochondrial Disease Week 2022

Abliva AB, a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in this year’s World Mitochondrial Disease Week through videos that will be released on Abliva’s website daily during the week, 18 – 24 September.

The videos will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases. Over the week, we will highlight the important role patients have played in informing our strategy, discuss Abliva’s efforts to treat mitochondrial disease patients with our two novel, first-in class compounds, KL1333 and NV354, and hear from a patient, Daniela Gallo, about her struggles with the disease.